Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown. This is a post hoc analysis of patients enrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Soc Nephrol
Autori principali: Geetha, Duvuru, Specks, Ulrich, Stone, John H., Merkel, Peter A., Seo, Philip, Spiera, Robert, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Fessler, Barri J., Ding, Linna, Tchao, Nadia K., Ikle, David, Jepson, Brett, Brunetta, Paul, Fervenza, Fernando C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2015
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378104/
https://ncbi.nlm.nih.gov/pubmed/25381429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014010046
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi